ASH News Daily 2015 - Day 2 - (Page A-1)

ASH NewS DAily ® 57th Annual Meeting of the American Society of Hematology Issue 2, Section A Sunday, December 6, 2015 Orlando, FL Read this issue online at www.hematology.org/ashnewsdaily2015_sunday Follow us on Twitter using #ASH15 Schedule Adventures in Safecracking: More Forward Movement in the Fight Against Myeloma By Michaela Liedtke, MD 7:30 - 9:00 a.m. Special Scientific Symposium on Overcoming the Barrier of TP53 Dysfunction to Cure Blood Cancers Orange County Convention Center (Hall E1) I n the 1967 movie "Grand Slam" a mild-mannered professor recruits an international team of experts to pull off a Brazilian jewel heist. One-by-one the experts chip away at the layers of protection that defend the notorious safe filled with diamonds. Just as in Rio, attendees of the Saturday morning multiple myeloma (MM) session witnessed 11:15 a.m. - 12:15 p.m. Continuing Conversations with the Speakers Orange County Convention Center (W232A; Lecture Hall W300; W303) 11:15 a.m. - 12:15 p.m. Featured Topic Discussion: Gene Therapy Orange County Convention Center (Tangerine 1 - WF1) 11:15 a.m. - 12:30 p.m. ASH Practice Partnership Lunch Hyatt Regency Orlando (Orlando Ballroom L) 12:30 - 1:30 p.m. ASH/EHA Joint Symposium Orange County Convention Center (Hall D) 1:30 - 2:00 p.m. Announcement of Awards Orange County Convention Center (Hall D) 2:00 - 4:00 p.m. Plenary Scientific Session 4:30 - 5:45 p.m. The Epic Story of Blood Orange County Convention Center (Chapin Theater, W320) 7:00 - 8:00 p.m. The HVO Volunteer Experience: Sharing Your Hematology Expertise Globally Orange County Convention Center (W305) IN THIS SECTION RBCs A-2 T-Cell Therapy A-4 Cultural Significance of Blood B-20 How to Tweet A-14 Dr. Ivo Touw delivers the Thomas H. Ham-Louis R. Wasserman Lecture in recognition of his pioneering work in the field of severe congenital neutropenia. a series of gains in therapy for multiple myeloma, and the results are some sparkling advances, both in patients with newly diagnosed and relapsed or refractory MM. Among the most exciting trials were those of two recently FDA-approved monoclonal antibodies for the treatment of relapsed or refractory MM. Dr. Saad Usmani presented combined results from two studies, GEN501 and Sirius - both of which used daratumumab (DARA), a human CD38-targeting monoclonal antibody. Patients were heavily pretreated with proteasome inhibitors, immunomodulatory agents (IMiD)s and autologous stem cell transplantation (ASCT), and over 90% were refractory to their last regimen. The combined analysis included 148 patients treated with DARA at a dose of 16 mg/kg. Infusion reactions were common (46%), but manageable, and usually limited to the first infusion. The overall response rate was 31% with an impressive 13% »» MYELOMA Page A-22 MoAbs and BiTEs and HDACs, Oh My! By Matthew Matasar, MD I n the rapidly expanding menagerie of therapeutics available in the management of both malignant and nonmalignant hematologic diseases, it can be difficult to keep up, let alone develop a deep understanding of each new agent and how it fits into the broader therapeutic landscape. On Saturday, Drs. Kenneth Bauer, Anjali Advani, and Sagar Lonial formally introduced us to three new agents recently approved by the U.S. Food and Drug Administration (FDA): idarucizumab, blinatumomab, and panobinostat. Dr. Kenneth Bauer spoke first on idarucizumab, a fully humanized monoclonal antibody fragment with high binding affinity for the oral direct thrombin inhibitor dabigatran, which "selectively and immediately neutralizes its anticoagulant activity." Dabigatran is the only of the four FDA-approved direct oral an- ticoagulants that targets thrombin »» DRUGS Page A-6  http://www.hematology.org/ashnewsdaily2015_sunday

Table of Contents for the Digital Edition of ASH News Daily 2015 - Day 2

In This Section

ASH News Daily 2015 - Day 2

https://www.nxtbookmedia.com